Competitive NMDA receptor antagonist.
Sold with the permission of Eli Lilly and Company.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 277.26. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.61 mL||18.03 mL||36.07 mL|
|5 mM||0.72 mL||3.61 mL||7.21 mL|
|10 mM||0.36 mL||1.8 mL||3.61 mL|
|50 mM||0.07 mL||0.36 mL||0.72 mL|
References are publications that support the products' biological activity.
Borowicz et al (1996) Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia 37 618 PMID: 8681893
Ellison (1994) Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5 2688 PMID: 7696633
If you know of a relevant reference for LY 235959, please let us know.
View Related Products by Product Action
Keywords: LY 235959, supplier, Competitive, NMDA, antagonist, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, LY235959, NMDA, Receptors, NMDA, Receptors, Tocris Bioscience
2 Citations for LY 235959
Citations are publications that use Tocris products. Selected citations for LY 235959 include:
Fowler et al (2011) Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471 597 PMID: 21278726
Kenny et al (2009) NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34 266 PMID: 18418357
Do you know of a great paper that uses LY 235959 from Tocris? If so please let us know.
LY 235959 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.